<DOC>
	<DOCNO>NCT00282451</DOCNO>
	<brief_summary>This trial conduct Africa Middle East . The objective study compare glycemic control Biphasic insulin Aspart 30 twice daily Biphasic insulin Aspart 30 twice daily plus Insulin Aspart , insulin treatment without metformin , subject type 2 diabetes , previously treat Biphasic Human Insulin 30/70 .</brief_summary>
	<brief_title>Effect Biphasic Insulin Compared Biphasic Insulin Combined With Insulin Aspart , With Without Metformin Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetic subject Current treatment Biphasic Human Insulin 30/70 twice daily alone combination oral hypoglycaemic agent least 3 month prior enter trial HbA1c least 12 % Willing able perform self blood glucose monitoring ( SMBG ) History drug alcohol dependence Receipt investigational drug within last month prior trial Anticipated change dose prescription medication , may influence glucose regulation ( Mono Amino Oxidaseinhibitors , non selective betaadrenergic agent , anabolic steroid systemic glucocorticoid ) Severe uncontrolled hypertension Recurrent severe hypoglycemia judge investigator Any disease condition , Investigator feel , would interfere trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>